ChromaDex Announces Distribution Agreement with Glanbia Nutritionals
Partnering with a large, exceptionally strong company like Glanbia is a tremendous next step in expanding pTeroPure’s adoption into numerous consumer products, said William Spengler, President of ChromaDex.
Jan 26 2012 --- ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of its branded patent-pending pterostilbene, pTeroPure, announced it has signed a letter of intent with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company, for the distribution of pTeroPure. Glanbia Nutritionals will serve as the primary distributor of pTeroPure in North America.
pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan, and is the central ingredient in its recently launched BluScience line of dietary supplements.
pTeroPure is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (an antioxidant phytochemical that tends to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
“Partnering with a large, exceptionally strong company like Glanbia is a tremendous next step in expanding pTeroPure’s adoption into numerous consumer products. With our upcoming human clinical data release and our various patents pending, in combination with Glanbia’s strong distribution base, we are now very well-positioned to more rapidly accelerate our national expansion of pTeroPure,” said William Spengler, President of ChromaDex.
“ChromaDex’s pTeroPure is an excellent addition to our product portfolio due to its superior bioavailability and range of potential health benefits,” said Richard Hazel, CEO of Glanbia Nutritionals (NA), Inc. “The new distribution agreement will allow us to utilize our extensive market experience and national sales resources towards promoting ChromaDex’s innovative new product line and will benefit Glanbia Nutritionals by strengthening our position as a leader in the ingredients industry.”
